Brief: Lantern Pharma Reports Additional Positive Lp-184 Phase 1A Results Showing Durable Disease Control In Heavily Pre-Treated Advanced Cancer Patients
03/12/2025 13:41
Dec 3 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA : REPORTS ADDITIONAL POSITIVE LP-184 PHASE 1A RESULTS SHOWING DURABLE DISEASE CONTROL IN HEAVILY PRE-TREATED ADVANCED CANCER PATIENTS LANTERN PHARMA INC: CLINICAL TRIAL MET ALL PRIMARY ENDPOINTS FOR SAFETY, TOLERABILITY, AND ESTABLISHED A CLEAR RECOMMENDED PHASE 2 DOSE Source text: ID:nBw50QGYwa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments